Drugs News and Research

RSS

Need for better understanding potential dangers of prescription painkillers

In response to a study published in the April issue of the American Journal of Preventive Medicine called "Hospitalizations for Poisoning by Prescription Opioids, Sedatives, and Tranquilizers," the Waismann Method of Opiate Detoxification is urging Americans to take measures to better understand and recognize the potential dangers and addictive nature of prescription painkillers.

22 Apr 2010

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

A new study by researchers at The George Washington University School of Medicine and Health Sciences' Department of Biochemistry and Molecular Biology raises hope that autism may be more easily diagnosed and that its effects may be more reversible than previously thought.

22 Apr 2010

GUMC researchers awarded grant to discover and develop new smoking cessation drugs

A Georgetown University Medical Center research team has been awarded a grant from the National Institute on Drug Abuse to discover and develop new smoking cessation drugs based on an unconventional theory about nicotine addiction. Kenneth Kellar, PhD, a professor of pharmacology at GUMC is principal investigator of the five year grant totaling $4.6 million.

22 Apr 2010

Colorado Governor moves forward with implementing reforms; Nevada community health centers feel financial pinch

In Colorado, "Gov. Bill Ritter signed four bills he promised will rein in skyrocketing health care costs on Tuesday and appointed a director who will oversee 10 state agencies to implement the Obama administration's new health care plan.

22 Apr 2010

Positive results from preclinical EP-302 program presented at AACR 2010

Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells.

22 Apr 2010

H1N1 flu epidemic has lessons to offer health care providers: Anesthesia Progress

The H1N1 flu epidemic has lessons to offer health care providers. The limited amount of vaccine available initially left pregnant women, small children with medical conditions, and other high-risk populations waiting in long lines. The problems encountered in reaching certain segments of the population apply to the provision of dental care as well as other disciplines.

22 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

Medical technology innovation strives for personal focus, cost-efficiency

Medtronic CEO Bill Hawkins says the products made by his company, like pacemakers, insulin pumps and neurostimulators are the "ultimate personal technologies," according to CNNMoney. He said a shift in his industry is moving towards health information technology that people will depend on and use with their cell phones and laptops.

22 Apr 2010

Radical prescription drug reform in New Zealand

Getting access to the latest medication may become a costly affair for New Zealanders. Talks on getting a Trans Pacific Strategic Economic Partnership between the US and New Zealand are taking place. The Researched Medicines Industry Association expects reforms from Pharmac the government’s drug buying agency if the deal is to go through. Some international drug companies have been angered by the control on drugs spending by Pharmac.

22 Apr 2010

Penn State researchers to test education program on patients with high blood pressure

When it comes to chronic diseases, knowledge is power, according to Penn State researchers who will test an education program on patients with high blood pressure to help them manage their disease.

22 Apr 2010

Mail-order drug provider identifies $163B in potential prescription drug savings

A study by Express Scripts, a mail-order prescription drug provider, said Tuesday that an "estimated $163 billion in health care spending could be saved each year if patients took their medicines as prescribed, chose generic drugs and other low-cost alternatives, and had their prescriptions delivered by mail," the St. Louis Post-Dispatch reports. Express Scripts released its report at a two-day conference for clients in St. Louis.

22 Apr 2010

As more reform specifics emerge, so do questions, answers and impacts

As details of health reform policies shake out, questions, answers and consequences are emerging.

22 Apr 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

NO-naproxen blocks molecular changes leading to colorectal cancer development

Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

22 Apr 2010

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.

22 Apr 2010

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Icagen, Inc. today announced that results from a study of ICA-105665 in patients with photosensitive epilepsy will be presented at the Tenth Eilat Conference on New Antiepileptic Drugs on Tuesday, April 27, 2010 in Eilat, Israel. The presentation will be made by Dorothee Kasteleijn-Nolst Trenite, MD, University Medical Centre Utrecht and Universita di Roma Sapienza II, Rome, Italy.

21 Apr 2010

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm Inc. today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.

21 Apr 2010

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.

21 Apr 2010

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.

21 Apr 2010

Drugs News and Research

Need for better understanding potential dangers of prescription painkillers

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

GUMC researchers awarded grant to discover and develop new smoking cessation drugs

Colorado Governor moves forward with implementing reforms; Nevada community health centers feel financial pinch

Positive results from preclinical EP-302 program presented at AACR 2010

H1N1 flu epidemic has lessons to offer health care providers: Anesthesia Progress

Research findings may help personalize use of statins, scientists say

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

Medical technology innovation strives for personal focus, cost-efficiency

Radical prescription drug reform in New Zealand

Penn State researchers to test education program on patients with high blood pressure

Mail-order drug provider identifies $163B in potential prescription drug savings

As more reform specifics emerge, so do questions, answers and impacts

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

NO-naproxen blocks molecular changes leading to colorectal cancer development

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News